NBC News

Endocyte to Present Final PRECEDENT Study Data on Targeted Therapeutic EC145 and Companion Imaging Diagnostic EC20 at ASCO Annual Meeting

WEST LAFAYETTE, Ind., May 19, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging ...
NBC News

Endocyte's EC145 Meets Primary Endpoint in Phase 2 Study, Demonstrating 85 Percent (2.3 month) Improvement in Median Progression-Free Survival for Treatment of Platinum ...

Get unlimited access to ad-free articles and exclusive content. - 260 Percent (4.0 Month) Increase in Median Progression-Free Survival in Folate Receptor Positive Patient Subgroup - Plan to File for ...
Morningstar

VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO ...

Initial Study to Evaluate Entolimod™ for Gastrointestinal Tissue Preservation in Partial-Body Acute Radiation Syndrome — an Indication for Which No Currently Approved or Stockpiled Countermeasure Has ...
Yahoo Finance

Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data

Wednesday, Sage Therapeutics Inc (NASDAQ:SAGE) announced topline results from the PRECEDENT Phase 2 study of dalzanemdor (SAGE-718) in people with mild cognitive impairment in Parkinson’s Disease. The ...
Finanznachrichten

Tivic Health Systems, Inc.: Valion Bio Receives First FDA-precedent Study Protocol From Niaid For Entolimod; Federal Agency To Fully Fund Bla-enabling In Vivo Program And Co ...

Initial Study to Evaluate Entolimod for Gastrointestinal Tissue Preservation in Partial-Body Acute Radiation Syndrome - an Indication for Which No Currently Approved or Stockpiled Countermeasure Has ...